Evidence map›Paper›PMID 40544157›Full record

ArticleSignal transduction and targeted therapy2025

TSC22 domain family member 3 links natural killer cells to CD8+ T cell-mediated drug hypersensitivity.

Lele Sun, Pengcheng Huai, Zhenzhen Wang, Qing Zhao, Yingjie Lin, Tingting Liu, Xiaotong Xue, Suiting Ao, Jiabao You, Yonghu Sun and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lele SunDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Pengcheng HuaiDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Zhenzhen WangDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.ORCID 0000-0001-5927-2471
Qing ZhaoDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Yingjie LinDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Tingting LiuDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Xiaotong XueDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Suiting AoDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Jiabao YouDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Yonghu SunDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Zihao MiDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China.
Joshua GardnerMRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutic, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID 0000-0002-4520-108X
Paul J ThomsonMRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutic, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Dean J NaisbittMRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutic, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Xiaoli MengMRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutic, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID 0000-0002-7774-2075
Jianjun LiuLaboratory of Human Genomics, Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.
Hong LiuDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China. hongyue2519@hotmail.com.
Furen ZhangDermatology Hospital of Shandong First Medical University, Jinan, Shandong, China. zhangfuren@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe cutaneous adverse drug reactions (SCARs) are life-threatening diseases, which are associated with human leukocyte antigen (HLA) risk variants. However, the low positive predictive values of HLA variants suggest additional factors influence disease susceptibility. Using dapsone hypersensitivity syndrome (DHS) as a paradigm for SCARs, we show that the DHS patients harbor a sex-related global reduction in blood NK cells, contributing to the higher incidence of reactions in females. Single-cell RNA sequencing revealed a decrease in the immunoregulatory CD56

Indexed as

CD8-Positive T-LymphocytesDrug HypersensitivityKiller Cells, NaturalAdultAnimalsFemaleHumansInterleukin-15MaleMiceInterleukin-15

Identifiers

PMID40544157
PMCPMC12182574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.